Henry Ford Health

Henry Ford Health Scholarly Commons
Hematology Oncology Articles

Hematology-Oncology

11-3-2021

Discovery of the pancreatic basal cell: a new candidate for an
adult stem cell emerges
Simone Benitz
Howard C. Crawford
Henry Ford Health, hcrawfo1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/
hematologyoncology_articles

Recommended Citation
Benitz S, and Crawford H. Discovery of the pancreatic basal cell: a new candidate for an adult stem cell
emerges. Gut 2021.

This Article is brought to you for free and open access by the Hematology-Oncology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Hematology Oncology Articles by an authorized administrator of
Henry Ford Health Scholarly Commons.

Discovery of the pancreatic basal cell: a
new candidate for an adult stem
cell emerges
Simone Benitz, Howard Crawford  
Pancreatic
ductal
adenocarcinoma
(PDAC) is a devastating disease and the
seventh cause of cancer-
related death
worldwide.1 Notably, clinical characteristics, response to chemotherapy and
progression of PDAC can vary among
patients. Thus, huge efforts on the
molecular profiling of cancer specimens
have been undertaken during the last
decade. Large-
scale gene expression
studies defined two main PDAC subtypes
with either a ‘classical’ or ‘basal-
like’
transcriptional signature, with patients
with the basal-
like subtype having a
significantly poorer overall survival.2–4
Basal cells are a cell type predominantly
located in the basal layer of stratified
and pseudostratified epithelia in several
tissues, including the skin, oesophagus,
lung and breast. Common basal cell
markers include keratin5 (KRT5) and
tumour protein P63 (TP63), a member
of the TP53 transcription factor family.
In the pulmonary airway, the oesophagus
and the mammary gland, basal cells serve
as multipotent stem cells or progenitor-
like cells which can give rise to organ-
specific, terminally differentiated cells
and thus have an important role in tissue
regeneration on injury.5 6
Though basal cells have been found in
several glandular organs, the pancreas
is not among them. Despite the enormous advances in single-
cell ‘omics’
technologies, no evidence has emerged
of a pancreatic basal cell population; in
fact, the existence of any sort of adult
pancreas stem cell reservoir has long
been debated. In the absence of a resident basal cell population, the basal-
like subtype of PDAC has been widely
believed to arise from tumour cell plasticity during progression.
In Gut, Martens et al combine a novel
tissue processing method with high-
resolution 3D imaging, an approach
termed FLIP-IT, to discover a rare basal
cell cohort in normal human pancreas
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specimens.7 The identified cells were
found in proximity to pancreatic duct cells
and stained positive for widely accepted
basal cell markers, such as ΔNp63, the ΔN
isoform of TP63. Moreover, the basal cell
cohort coexpresses GI stem cell markers,
such as Olfactomedin4 (OLFM4),
suggesting a potential role as progenitor
cell.
Importantly, the authors reveal that
the number of ΔNp63-positive cells was
significantly higher in chronic pancreatitis (CP), a risk factor for PDAC, as
well as in PDAC samples.7 The presence of a greater number of basal cells
in pathological conditions is consistent
with the stem or progenitor cell-like role
they play in other tissues.5 6 In PDAC, an
intriguing possibility is that the pancreatic basal cell serves as a cell of origin for
the basal-like PDAC subtype. To address
this, performance of lineage-
tracing
experiments and genetic manipulation
in mice would be the obvious choice.
However, the authors found no evidence
of a similar ΔNp63-expressing basal cell
population in the mouse pancreas, even
in CP or PDAC models, making their
study in a progressive mouse model
impossible.7 This lack of similarity to
the human condition also raises concerns
regarding the usefulness of mouse models
when studying certain aspects of pancreatic cancer development. Interestingly,
in organoid cultures generated from
larger murine pancreatic duct cells, the
authors were able to generate ΔNp63-
positive cells, suggesting that there may
be conditions that give rise to basal cells
in vivo as well. Initial analysis show that
in both the murine organoid culture as
well as human pancreas tissue, the identified basal cell population has a very low
proliferative capacity.7 Thus, it is likely
that these cells rather arise through
induced cellular plasticity rather than
expansion of pre-existing ΔNp63 cells.
With the ability to generate and culture
a ΔNp63-expressing cell cohort in vitro,
new avenues to dissect and identify regulatory networks emerge.
Prior to the discovery of a pancreatic
basal cell population, the only plausible
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explanation for the evolution of a basal-
like PDAC has been a classical-to-basal
reprogramming of pancreatic cancer
cells. Several lines of evidence point in
this direction. In vitro studies confirm
that ectopic expression of ΔNp63 in
pancreatic cancer cell lines induces a
basal gene expression signature accompanied by a loss of factors that define
classical cancer cell identity.8 9 Although
these studies clearly identify ΔNp63 as
master regulator of the basal phenotype, the events and regulatory mechanisms that induce the expression of this
transcription factor are also relatively
unknown. Recently published data
propose that an erosion of pancreas cell
identity with the concomitant loss of the
transcription factors GATA6, hepatocyte
nuclear factor (HNF)1a and 4a (HNF4a)
can drive the induction of ΔNp63 and its
dependent gene networks. However, the
exact gene regulatory mechanisms remain
elusive.10 By combining histological
analysis with whole-
genome and RNA
sequencing, Hayashi et al provide strong
evidence for intratumoral heterogeneity,
the coexistence of both subtypes within
single PDAC samples. Moreover, based
on their integrative analysis approach,
the authors propose that PDAC evolves
from a cancer progenitor cell, from
which both classical and basal-like cells
arise. Phylogenetic analyses mainly based
on genetic alterations provide a clear
indication for this scenario, making the
existence of a classical-
to-
basal reprogramming in pancreatic cancer cells
a likely phenomenon.4 However, the
discovery of a normal basal cell population adds another possible origin for
the basal-like PDAC. Understanding the
unique biology of the basal-like phenotype, whether intrinsic or acquired, will
be crucial to targeting this especially
deadly form of pancreatic cancer.
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